Fischer Imaging will remain listed on the Nasdaq exchange at least until Nov. 14, at which time the company must have filed necessary documentation or face delisting. In order to remain on the exchange, Fischer must complete an amended Form 10-Q for the
Fischer Imaging will remain listed on the Nasdaq exchange at least until Nov. 14, at which time the company must have filed necessary documentation or face delisting. In order to remain on the exchange, Fischer must complete an amended Form 10-Q for the quarter ended June 30, 2002, including an affirmative disclosure that the report has been reviewed consistent with SAS 71, as well as a Form 10-Q for the quarter ended Sept. 30, 2002. Alliance Pharmaceutical had no such recourse. The company announced Oct. 17 its delisting from the exchange for failure to meet certain requirements. The company¹s stock is now being traded on Nasdaq's over-the-counter bulletin board.
Large Study Affirms Safety of Ultrasound Enhancing Agents for Echocardiography
May 16th 2025Those receiving ultrasound enhancing agents (UEAs) for transthoracic or stress echocardiography had lower odds of all-cause death in comparison to patients who did not have UEAs, according to a nationwide study involving 11.4 million patients.
BrightHeart Garners Third FDA Clearance for AI-Powered Assessments of Fetal Heart Ultrasound
May 14th 2025The latest FDA 510(k) clearance is for B-Right Views, an AI-enabled device, which provides automated detection of required views necessary for second- and third-trimester fetal heart ultrasound exams.